SI-BONE, Inc. (NASDAQ:SIBN) Given Consensus Recommendation of “Buy” by Analysts

Shares of SI-BONE, Inc. (NASDAQ:SIBN) have received an average recommendation of “Buy” from the six brokerages that are covering the stock, Marketbeat reports. Six research analysts have rated the stock with a buy rating. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $24.50.

SIBN has been the topic of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 target price on shares of SI-BONE in a research note on Tuesday, February 25th. Truist Financial reaffirmed a “buy” rating and set a $22.00 price objective (up previously from $18.00) on shares of SI-BONE in a research report on Tuesday, February 25th. Finally, Needham & Company LLC raised their target price on shares of SI-BONE from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Tuesday, February 25th.

SI-BONE Price Performance

Shares of NASDAQ SIBN opened at $16.06 on Monday. The business has a 50-day moving average of $16.44 and a 200-day moving average of $14.89. The company has a market capitalization of $681.80 million, a price-to-earnings ratio of -17.46 and a beta of 1.17. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. SI-BONE has a 1-year low of $11.70 and a 1-year high of $19.16.

SI-BONE (NASDAQ:SIBN) last issued its quarterly earnings results on Monday, February 24th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The firm had revenue of $49.00 million during the quarter, compared to the consensus estimate of $48.87 million. On average, equities analysts anticipate that SI-BONE will post -0.78 EPS for the current fiscal year.

Insider Buying and Selling at SI-BONE

In other news, CFO Anshul Maheshwari sold 5,304 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $13.91, for a total value of $73,778.64. Following the completion of the transaction, the chief financial officer now directly owns 189,319 shares in the company, valued at $2,633,427.29. This trade represents a 2.73 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Anthony J. Recupero sold 3,670 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $13.90, for a total transaction of $51,013.00. Following the transaction, the insider now owns 222,814 shares in the company, valued at $3,097,114.60. This represents a 1.62 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 9,311 shares of company stock valued at $130,356. Company insiders own 3.90% of the company’s stock.

Hedge Funds Weigh In On SI-BONE

Several large investors have recently made changes to their positions in SIBN. Harbor Capital Advisors Inc. increased its holdings in shares of SI-BONE by 222.5% in the third quarter. Harbor Capital Advisors Inc. now owns 620,490 shares of the company’s stock valued at $8,674,000 after buying an additional 428,110 shares in the last quarter. Champlain Investment Partners LLC raised its position in shares of SI-BONE by 14.7% during the third quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company’s stock worth $39,145,000 after purchasing an additional 358,821 shares during the period. Silvercrest Asset Management Group LLC lifted its holdings in shares of SI-BONE by 21.9% during the fourth quarter. Silvercrest Asset Management Group LLC now owns 1,953,806 shares of the company’s stock valued at $27,392,000 after purchasing an additional 350,970 shares during the last quarter. American Century Companies Inc. lifted its holdings in shares of SI-BONE by 11.0% during the fourth quarter. American Century Companies Inc. now owns 2,378,068 shares of the company’s stock valued at $33,341,000 after purchasing an additional 236,167 shares during the last quarter. Finally, Impax Asset Management Group plc boosted its position in shares of SI-BONE by 41.3% in the 3rd quarter. Impax Asset Management Group plc now owns 758,521 shares of the company’s stock valued at $10,604,000 after purchasing an additional 221,604 shares during the period. Institutional investors own 98.11% of the company’s stock.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.